Gyre Therapeutics, Inc. GYRE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $117.05M+16.3% | $116.59M+10.2% | $107.27M+2.1% | $102.19M-8.4% | $100.64M-13.0% | ||
| $5.75M+51.3% | $5.42M+39.4% | $4.85M+22.6% | $4.18M-0.1% | $3.8M-15.4% | ||
| $111.3M+14.9% | $111.17M+9.1% | $102.42M+1.3% | $98.01M-8.7% | $96.84M-12.9% | ||
| 95.1%-1.1pp | 95.4%-1.0pp | 95.5%-0.8pp | 95.9%-0.3pp | 96.2%+0.1pp | ||
| $17.34M+34.0% | $13.7M+13.9% | $12.6M-2.2% | $13.01M-0.8% | $12.94M-2.9% | ||
| $68.47M+22.7% | $65.18M+13.3% | $58.22M+1.9% | $56.59M-1.3% | $55.81M-8.4% | ||
| $23.07M+30.6% | $20.8M+29.1% | $19.57M-5.5% | $19.07M+5.8% | $17.67M+8.2% | ||
| $117.19M+29.8% | $105.1M+17.3% | $95.23M-47.4% | $92.85M-48.2% | $90.28M-50.3% | ||
| -$141K-101% | $11.49M-28.9% | $12.03M+116% | $9.34M+114% | $10.37M+116% | ||
| -0.1%-10.4pp | 9.9%-5.4pp | 11.2%+83.7pp | 9.1%+69.7pp | 10.3%+67.2pp | ||
| -$1.58M+5.4% | -$1.51M+9.3% | -$945K-261% | -$1.75M-14.9% | -$1.67M-104% | ||
| $630K-95.9% | $14.5M-37.5% | $15.27M+120% | $11.58M+116% | $15.37M+122% | ||
| $4.28M+16.4% | $4.56M-14.4% | $3.46M-40.5% | $2.84M-66.3% | $3.68M-59.2% | ||
| —— | —— | $6.75M+109% | $4.26M+105% | $7.35M+109% | ||
| —— | —— | $0.03+102% | $0.01+101% | $0.02+101% | ||
| —— | —— | $0.07+105% | $0.04+103% | $0.08+106% | ||
| 401.2M-1.9% | 411.8M+0.5% | 410.9M+10.1% | 409.6M+17.2% | 409.1M+25.4% | ||
| 360.6M+5.2% | 355.7M+4.8% | 351.5M+9.8% | 346.3M+16.1% | 342.7M+24.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.58M+5.4% | -$1.51M+9.3% | -$945K-261% | -$1.75M-14.9% | -$1.67M-104% | ||
| $117.05M+16.3% | $116.59M+10.2% | $107.27M+2.1% | $102.19M-8.4% | $100.64M-13.0% | ||
| -$141K-101% | $11.49M-28.9% | $12.03M+116% | $9.34M+114% | $10.37M+116% | ||
| $2.48M-79.4% | $13.97M-21.1% | $14.32M+119% | $11.42M+117% | $12.03M+119% | ||
| $2.48M-79.4% | $13.97M-21.1% | $14.32M+119% | $11.42M+117% | $12.03M+119% | ||
| 2.1%-9.8pp | 12%-4.8pp | 13.4%+84.5pp | 11.2%+70.7pp | 12%+67.8pp | ||
| -$141K-101% | $11.49M-28.9% | $12.03M+116% | $9.34M+114% | $10.37M+116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $117.0M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $1.9M over the trailing twelve months, a 6.3% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 95.1% and operating margin is -0.1%, with a 6.3% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.07.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
